Trial Profile
Analysis of JCV serology for progressive multifocal leukoencephalopathy (PML) risk stratification in Natalizumab treated patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Therapeutic Use
- 11 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology